ID   TYK-nu.CP-r
AC   CVCL_3221
AS   CVCL_EQ58
SY   TYK-nu (R); TYKNU CPR; TYKnuCPr; TYK-nu-CisR; Tyk-nu-cisR; TYKnuCisR; TyknuCisR
DR   EFO; EFO_0006767
DR   ArrayExpress; E-MTAB-2706
DR   cancercelllines; CVCL_3221
DR   CGH-DB; 383-2
DR   CGH-DB; 9360-4
DR   EGA; EGAS00001000610
DR   GEO; GSM851947
DR   JCRB; JCRB0234.1
DR   PharmacoDB; TYKnu_CPr_1615_2019
DR   PRIDE; PXD003668
DR   Wikidata; Q54973462
RX   PubMed=2647872;
RX   PubMed=11330945;
RX   PubMed=12417041;
RX   PubMed=22710073;
RX   PubMed=25485619;
RX   PubMed=26589293;
RX   PubMed=27561551;
CC   Population: Japanese.
CC   Doubling time: 48 hours (PubMed=2647872).
CC   HLA typing: A*02:01,26:03; B*35:08,58:05; C*03:03,07:02; DRB1*13:07,15:01 (PubMed=26589293).
CC   Karyotypic information: Deletion of chromosome 7q (PubMed=2647872).
CC   Selected for resistance to: ChEBI; CHEBI_27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
CC   Omics: Proteomics.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
ST   Source(s): JCRB=JCRB0234.1; PubMed=22710073
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 10,11
ST   D16S539: 9,10
ST   D18S51: 13
ST   D19S433: 14.2
ST   D21S11: 32.2
ST   D2S1338: 18,24
ST   D3S1358: 15
ST   D5S818: 12,13
ST   D7S820: 10
ST   D8S1179: 10,15
ST   FGA: 24
ST   TH01: 9
ST   TPOX: 9,11
ST   vWA: 14,16
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1776 ! TYK-nu
SX   Female
AG   38Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 27-11-25; Version: 28
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn, Christiaan
RA   Durinck, Steffen
RA   Stawiski, Eric W.
RA   Haverty, Peter M.
RA   Jiang, Zhao-Shi
RA   Liu, Han-Bin
RA   Degenhardt, Jeremiah
RA   Mayba, Oleg
RA   Gnad, Florian
RA   Liu, Jin-Feng
RA   Pau, Gregoire
RA   Reeder, Jens
RA   Cao, Yi
RA   Mukhyala, Kiran
RA   Selvaraj, Suresh K.
RA   Yu, Ma-Mie
RA   Zynda, Gregory J.
RA   Brauer, Matthew J.
RA   Wu, Thomas D.
RA   Gentleman, Robert Clifford
RA   Manning, Gerard
RA   Yauch, Robert L.
RA   Bourgon, Richard
RA   Stokoe, David
RA   Modrusan, Zora
RA   Neve, Richard M.
RA   de Sauvage, Frederic J.
RA   Settleman, Jeffrey
RA   Seshagiri, Somasekar
RA   Zhang, Ze-Min
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=11330945; DOI=10.1006/gyno.2001.6132;
RA   Watanabe, Takafumi
RA   Imoto, Issei
RA   Kosugi, Yoshinori
RA   Ishiwata, Isamu
RA   Inoue, Satoshi
RA   Takayama, Masaomi
RA   Sato, Akira
RA   Inazawa, Johji
RT   "A novel amplification at 17q21-23 in ovarian cancer cell lines
RT   detected by comparative genomic hybridization.";
RL   Gynecol. Oncol. 81:172-177(2001).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers, Jelle
RA   Boegel, Sebastian
RA   Bukur, Thomas
RA   Byl, Marius
RA   Goerges, Sebastian
RA   Sorn, Patrick
RA   Loewer, Martin
RA   Sahin, Ugur
RA   Castle, John C.
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27561551; DOI=10.1038/ncomms12645; PMCID=PMC5007461;
RA   Coscia, Fabian
RA   Watters, Karen M.
RA   Curtis, Marion
RA   Eckert, Mark A.
RA   Chiang, Chun-Yi
RA   Tyanova, Stefka
RA   Montag, Anthony
RA   Lastra, Ricardo R.
RA   Lengyel, Ernst Robert
RA   Mann, Matthias
RT   "Integrative proteomic profiling of ovarian cancer cell lines reveals
RT   precursor cell associated proteins and functional status.";
RL   Nat. Commun. 7:12645.1-12645.14(2016).
//
RX   PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x; PMCID=PMC5926887;
RA   Watanabe, Takafumi
RA   Imoto, Issei
RA   Katahira, Tomoyuki
RA   Hirasawa, Akira
RA   Ishiwata, Isamu
RA   Emi, Mitsuru
RA   Takayama, Masaomi
RA   Sato, Akira
RA   Inazawa, Johji
RT   "Differentially regulated genes as putative targets of amplifications
RT   at 20q in ovarian cancers.";
RL   Jpn. J. Cancer Res. 93:1114-1122(2002).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677;
RA   Korch, Christopher T.
RA   Spillman, Monique Ann
RA   Jackson, Twila A.
RA   Jacobsen, Britta M.
RA   Murphy, Susan K.
RA   Lessey, Bruce Arthur
RA   Jordan, Virgil Craig
RA   Bradford, Andrew Peter
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=2647872;
RA   Yoshiya, Norio
RA   Adachi, Shigemi
RA   Misawa, Yoshio
RA   Yuzawa, Hideo
RA   Honda, Tatsuo
RA   Kanazawa, Koji
RA   Takeuchi, Shoshichi
RA   Tanaka, Kohei
RT   "Isolation of cisplatin-resistant subline from human ovarian cancer
RT   cell line and analysis of its cell-biological characteristics.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 41:7-14(1989).
//